NEXTGEN HEALTHCARE, INC (NXGN)
(Delayed Data from NSDQ)
$19.75 USD
+0.51 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.75 USD
+0.51 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Surmodics' Pounce Thrombus Retrieval System Gets FDA Nod
by Zacks Equity Research
The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.
NXGN or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. TRHC: Which Stock Is the Better Value Option?
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Here's Why You Should Add NextGen Stock to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
Schrodinger (SDGR) Jumps: Stock Rises 8.5%
by Zacks Equity Research
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Fed to Hold Rates Near Zero Until End of 2023: 5 Big Winners
by Tirthankar Chakraborty
The Fed sees rates near zero until the economy reaches full employment and inflation runs "moderately" above its 2% goal. But these aren't happening soon and investors can get used to low rates.
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.
Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
by Urmimala Biswas
Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
NXGN vs. TRHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
NXGN vs. TRHC: Which Stock Is the Better Value Option?
4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus
by Debanjana Dey
Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
NextGen Healthcare Introduces New Behavioral Health Suite
by Zacks Equity Research
NextGen Healthcare's (NXGN) new behavioral health suite aims to provide whole person care with support services for healthcare providers and clinicians.
Strength Seen in Fulgent Genetics (FLGT): Stock Soars 11.6%
by Zacks Equity Research
Fulgent Genetics (FLGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
OPKO Health's BioReference Laboratories Introduces NGS Assay
by Zacks Equity Research
OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.
Why Is Nextgen Healthcare (NXGN) Up 5.6% Since Last Earnings Report?
by Zacks Equity Research
Nextgen Healthcare (NXGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NXGN vs. TRHC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NXGN vs. TRHC: Which Stock Is the Better Value Option?
Here's Why You Should Add NextGen Stock to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
NXGN or HMSY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. HMSY: Which Stock Is the Better Value Option?
NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates
by Zacks Equity Research
NextGen (NXGN) benefited from its Recurring segment in Q1.
Nextgen Healthcare (NXGN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 133.33% and 13.70%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nextgen Healthcare (NXGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Nextgen Healthcare (NXGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nextgen Healthcare (NXGN) Up 4.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nextgen Healthcare (NXGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.